[logo] HealthTree Foundation
search person

Lenalidomide (Revlimid) Financial Assistance Program

Posted: Jan 27, 2017
Lenalidomide (Revlimid) Financial Assistance Program image

Patient assistance programs are available for some commonly used myeloma treatments – for the drug costs themselves and/or for co-pay assistance. Many of these programs are significantly underutilized, so please call and find out if these programs apply to you, even if you are not financially distressed.  The following support is offered by Celgene for the drug lenalidomide (REVLIMID®). No matter what type of insurance you have, or if you don’t have insurance or enough coverage, Celgene Patient Support® can help. When you enroll in Celgene Patient Support®, you will speak to the same Specialist every time you call. Your Specialist can help with:

  • Finding financial assistance to help pay for REVLIMID
  • Understanding your insurance plan or finding alternative coverage
  • Locating help with travel costs to and from your doctor’s office

How to Enroll in Celgene Patient Support®

  1. Online at www.CelgenePatientSupport.com
  2. Call us at 1-800-931-8691, Monday – Friday, 8am – 7pm ET, or fax us at 1-800-822-2496

What Celgene Patient Support® Provides

If you qualify, Celgene Patient Support® can help you:

  • Obtain co-pay assistance: You may be eligible for help to reduce your medication co-pay to $25 for REVLIMID. This depends on what kind of insurance coverage you have and Celgene Patient Support® can help you find assistance no matter what your insurance situation. Learn more.
  • Receive free medication: If you don’t currently have any health insurance or enough insurance to cover the cost of your medication, you may qualify for free Celgene medication. Learn more.
  • Cover travel costs: Celgene Patient Support® can help locate options to assist with the costs of traveling to and from your doctor’s office. Learn more.

Patient assistance programs are available for some commonly used myeloma treatments – for the drug costs themselves and/or for co-pay assistance. Many of these programs are significantly underutilized, so please call and find out if these programs apply to you, even if you are not financially distressed.  The following support is offered by Celgene for the drug lenalidomide (REVLIMID®). No matter what type of insurance you have, or if you don’t have insurance or enough coverage, Celgene Patient Support® can help. When you enroll in Celgene Patient Support®, you will speak to the same Specialist every time you call. Your Specialist can help with:

  • Finding financial assistance to help pay for REVLIMID
  • Understanding your insurance plan or finding alternative coverage
  • Locating help with travel costs to and from your doctor’s office

How to Enroll in Celgene Patient Support®

  1. Online at www.CelgenePatientSupport.com
  2. Call us at 1-800-931-8691, Monday – Friday, 8am – 7pm ET, or fax us at 1-800-822-2496

What Celgene Patient Support® Provides

If you qualify, Celgene Patient Support® can help you:

  • Obtain co-pay assistance: You may be eligible for help to reduce your medication co-pay to $25 for REVLIMID. This depends on what kind of insurance coverage you have and Celgene Patient Support® can help you find assistance no matter what your insurance situation. Learn more.
  • Receive free medication: If you don’t currently have any health insurance or enough insurance to cover the cost of your medication, you may qualify for free Celgene medication. Learn more.
  • Cover travel costs: Celgene Patient Support® can help locate options to assist with the costs of traveling to and from your doctor’s office. Learn more.
The author Jennifer Ahlstrom

about the author
Jennifer Ahlstrom

Myeloma survivor, patient advocate, wife, mom of 6. Believer that patients can contribute to cures by joining HealthTree Cure Hub and joining clinical research. Founder and CEO of HealthTree Foundation. 

newsletter icon

Get the latest thought leadership on your Multiple Myeloma delivered straight to your inbox

Subscribe to the weekly newsletter for news, stories, clinical trial updates, and helpful resources and events with cancer experts.

Follow Us

facebook instagram linkedin tiktok youtube